Combination of novel DR5 targeting agonistic scFv antibody TR2-3 with cisplatin shows enhanced synergistic antitumor activity in vitro and in vivo

Article ID	Journal	Published Year	Pages	File Type
8526127	Biomedicine & Pharmacotherapy	2018	9 Pages	PDF

Abstract

Our findings suggest that cisplatin enhanced the antitumor activity of TR2-3 in COLO205 and MDA-MB-231 cancer cells through up-regulation of DR5 expression. The TR2-3 combined with cisplatin may be a promising treatment for cancer therapy.

Keywords

scFv TNF DR5 DR4 IPTG PBS MTT isopropyl β-D-1-thiogalactopyranoside Apoptosis cisplatin tumor necrosis factor Phosphate buffered saline TRAIL TNF-related apoptosis inducing ligand Single chain fragment variable Death receptor 4 death receptor 5